Diagnosis and Management of Anal Intraepithelial Neoplasia
For suspected anal intraepithelial neoplasia (AIN), perform digital rectal examination followed by high-resolution anoscopy with targeted biopsy for histologic confirmation; in high-risk patients with high-grade AIN, ablative therapy (particularly electrocautery) reduces progression to anal cancer by 57% compared to observation and is superior to topical agents. 1
Diagnostic Approach
Initial Clinical Evaluation
Digital rectal examination (DRE) is mandatory as the first-line assessment tool for detecting anal lesions in every patient with suspected AIN. 1, 2 This low-cost examination should specifically palpate for:
- Masses or indurated areas in the anal canal 2
- Superficial inguinal lymph nodes, particularly those medial and close to the pubis 2
- In women with low, anteriorly placed lesions, perform vaginal examination to assess vaginal or vaginal-septal involvement 2
Screening Tests for High-Risk Populations
Anal cytology is an effective screening tool, though its performance is highly operator-dependent. 1 Alternative screening strategies include:
- High-risk HPV testing alone (misses 14.2% of HSIL) 3
- Co-testing with hrHPV and cytology (≥ASCUS threshold misses only 4.4% of HSIL, though 79% require HRA referral) 3
- hrHPV testing with HPV16 genotyping 4
The International Anal Neoplasia Society recommends screening initiation at: 4
- Age 35 years for MSM and transgender women with HIV
- Age 45 years for other people with HIV and MSM/transgender women without HIV
- 10 years post-transplant for solid organ transplant recipients (incidence rises to 24.5–29.6 per 100,000 person-years after this interval) 1
- Within 1 year of diagnosis for persons with vulvar precancer or cancer
Definitive Diagnosis
High-resolution anoscopy (HRA) with targeted biopsy is mandatory in high-risk groups to exclude invasive cancer and confirm the AIN diagnosis. 1 The accuracy of HRA is strongly dependent on operator training and experience. 1
Histologic confirmation by biopsy of any suspicious lesion is required before initiating treatment. 1, 2 Several malignancies can mimic squamous cell carcinoma, including adenocarcinoma, melanoma, GIST, neuroendocrine tumor, and lymphoma. 2
Additional Workup
HIV testing should be performed in patients with unknown HIV status or those presenting with recurrent or multifocal AIN lesions. 1, 2
Women diagnosed with AIN must be screened concurrently for cervical, vulvar, and vaginal intraepithelial neoplasia due to shared HPV etiology. 1, 2
Treatment Strategy
High-Grade AIN Treatment
Topical or ablative therapy reduces progression to anal cancer by 57% compared with active monitoring in people living with HIV with high-grade AIN (9/4,459 vs 21/4,459 cases; median follow-up 25.8 months, p = 0.03). 1 This represents Level I evidence from a Phase III randomized trial.
Electrocautery is superior to topical agents (imiquimod, 5-fluorouracil) for overall clearance of AIN, based on a randomized trial of 246 HIV-positive MSM. 1 This is the highest-quality evidence available for treatment selection.
Topical Therapy Considerations
Imiquimod shows a higher response rate for perianal AIN than for intra-anal AIN. 1 This anatomic distinction is critical when selecting topical therapy.
Other ablative options include: 5, 6, 7
- Infrared coagulation
- Cryotherapy
- Laser therapy
- Surgical excision
Treatment Limitations
Recurrence of AIN is common after any treatment modality, necessitating lifelong surveillance. 1 Even with the 57% risk reduction from treatment, HIV-positive MSM have an 18% conversion rate from high-grade AIN to anal cancer over a median 2.3-year follow-up despite treatment. 1
Surveillance Protocol
Given the high recurrence rates, patients treated for high-grade AIN require intensive, long-term follow-up; the 57% risk reduction still leaves a substantial residual cancer risk. 1
Surveillance strategies vary but typically include: 8
- Physical examination every 6 months
- Annual anoscopy with or without biopsy
Abnormal screening results can temporarily worsen health-related quality of life in the weeks following testing. 1
Prevention
Quadrivalent HPV vaccine provides 77.5% efficacy in preventing grade 2/3 AIN among MSM aged 16–26 years. 1
The 9-valent HPV vaccine is projected to prevent an additional 464 anal cancer cases per year compared with the quadrivalent formulation. 1
Critical Pitfalls
No randomized trial has yet shown that screening reduces anal cancer mortality; clinicians should convey this uncertainty when discussing screening benefits. 1 Despite this limitation, the 57% reduction in cancer progression with treatment provides strong rationale for screening high-risk populations.
All suspicious anal lesions must be biopsied; clinicians should not assume benign pathology based solely on appearance. 2
Colonoscopy is not required for the work-up of anal squamous cell carcinoma because synchronous colonic lesions have not been reported in this disease. 2
The classification of low-grade versus high-grade AIN suffers from high interobserver variability, which can affect treatment decisions. 9 When in doubt, repeat biopsy or seek expert pathology review.